NEW YORK--(BUSINESS WIRE)--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Outset Medical, Inc. (“Outset” or “the Company”) (NASDAQ: OM). Investors who purchased Outset securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/OM.
Investigation Details
On August 7, 2024, Outset released its second quarter 2024 financial results. The Company missed consensus estimates by a considerable margin and lowered its full year 2024 outlook. According to the Company, the “changes [it] needs to make are entirely in [its] control” and will involve “shifts and adjustments” to its sales team and processes. Based on this news, shares of Outset fell by 68.53% on August 8, 2024.
What's Next?
If you are aware of any facts relating to this investigation or purchased Outset securities, you can assist this investigation by visiting the firm’s site: bgandg.com/OM. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660.
There is No Cost to You
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
Attorney advertising. Prior results do not guarantee similar outcomes.
